In this episode of The Peter Attia Drive, Peter Attia and Bob Kaplan address listener questions, primarily focusing on the utility of DNA kits and genetic testing for guiding nutrition, exercise, and longevity tactics. Attia expresses skepticism about the actionable value of current genetic tests like 23andMe for most common diseases such as cancer and cardiovascular disease, arguing that phenotypic data often provides more insightful and trackable metrics. He does, however, acknowledge the potential value of ApoE status for Alzheimer's risk assessment and discusses liquid biopsies for detecting somatic mutations in cancer. The conversation also touches on specific genes related to longevity and the limited impact of genetic predispositions on personalized nutrition and exercise plans, advocating for empirical determination instead.
Sign in to continue reading, translating and more.
Continue